Acasti Pharma (ACST) Stock Price, News & Analysis

Company Overview

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Key Stats

• Today's Range: $3.20 to $3.45
• 50-Day Range: $2.20 to $3.60
• 52-Week Range: $1.98 to $3.60
• Volume: 27,800 shs
• Average Volume: 22,722 shs
• Market Capitalization: $31.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Acasti Pharma Stock Analysis - MarketRank™

Acasti Pharma scored higher than 44% of companies evaluated by MarketBeat, and ranked 706th out of 971 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Acasti Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Acasti Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Acasti Pharma are expected to grow in the coming year, from ($1.11) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acasti Pharma is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acasti Pharma is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acasti Pharma has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.47% of the float of Acasti Pharma has been sold short.

Short Interest Ratio / Days to Cover

Acasti Pharma has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Acasti Pharma has recently increased by 19.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acasti Pharma does not currently pay a dividend.

Dividend Growth

Acasti Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.47% of the float of Acasti Pharma has been sold short.

Short Interest Ratio / Days to Cover

Acasti Pharma has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Acasti Pharma has recently increased by 19.63%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for ACST on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Acasti Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Acasti Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.51% of the stock of Acasti Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 6.08% of the stock of Acasti Pharma is held by institutions.

ACST Stock Analysis - Frequently Asked Questions

How have ACST shares performed this year?

Acasti Pharma's stock was trading at $2.89 at the beginning of the year. Since then, ACST stock has increased by 16.6% and is now trading at $3.37.
View the best growth stocks for 2024 here.

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) released its quarterly earnings results on Friday, June, 21st. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.30.

When did Acasti Pharma's stock split?

Shares of Acasti Pharma reverse split on Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of Acasti Pharma?

Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acasti Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), General Electric (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 6/21/2024
• Today: 11/16/2024
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACST
• CUSIP: N/A
• CIK: 1444192
• Web: www.acastipharma.com
• Phone: 45-0686-4555
• Fax: 45-0687-2272
• Employees: 32
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +196.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-12,850,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -13.61%
• Return on Assets: -11.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.86
• Quick Ratio: 7.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.57 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 9,399,000
• Free Float: 8,770,000
• Market Cap: $31.67 million
• Optionable: Not Optionable
• Beta: 1.52